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Abstract:Wereporthereonoureffortstodevelopnewstrategiesforthesynthesisofa-tocopherol,thebiological-
lymostsignificantmemberofthevitaminEfamily.Thisreviewcomprisesfivenewmethodstogeneratethechiral
chromaneofa-tocopherolwithoverallupto29%yieldfromcommerciallyavailablematerialandupto94%de.
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1. Introduction
Vitamin E comprises tocopherols 1–4 and 
tocotrienols 5–8 which can be isolated 
from all photosynthetic organisms (Fig. 1). 
These compounds exhibit various physio-
logically significant properties such as the 
modulation of signal transduction,[1] anti-
inflammatory action[2] and antioxidant re-
activity.[3] 
a-Tocopherol (1) is the biologically 
most important member of the vitamin E 
family as it acts as the best radical chain-
breaking antioxidant in tissues[4] and binds 
selectively to a transport protein[5] provid-
ing efficient bioavailability. The antioxi-
dant reactivity of the chromanol system 
has been investigated in detail[3] and is at-
tributed to stereoelectronic factors, i.e. the 
lone pair of O(1) is favorably oriented to 
stabilize the tocopheryl radical 9 produced 
by homolysis of the phenolic OH group 
(Scheme 1).
The isolation of pure 1 from natu-
ral sources is quite difficult because the 
compound appears in various amounts 
along with other vitamin E chromanols. 
The challenge to prepare chiral 1 results 
from the presence of stereogenic centers 
at C(2), C(4’), and C(8’). A comprehen-
sive review by Netscher describes the 
syntheses of racemic and enantiomeri-
cally enriched tocopherols up to 2006.[6] 
Since then we have developed several new 
approaches to chiral chromanols that are 
reviewed here. 
2. Results and Discussion
2.1 Biomimetic Synthesis of a- 
Tocopherol and a-Tocotrienol
The discovery of the enzyme tocoph-
erol cyclase from Cyanobacteria[7] and 
investigations of the substrate specific-
ity[8] and reaction mechanism[9] revealed 
that i) the enzyme cyclizes hydroquinone 
O
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R1=R2=Me: α-tocopherol (1)
R1=H, R2=Me: γ-tocopherol (2)
R1=Me, R2=H: β-tocopherol (3)
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precursors with chiral and unsaturated 
side chains leading to 2 and 6, respective-
ly, with the comparable efficiency; and ii) 
the very hydrophobic 42 kD protein oper-
ates by si protonation of the double bond 
and concomitant re attack of the phenol 
(Scheme 2).
In view of the weak acidity of amino 
acids available in the active site of the pro-
tein it was suggested[10] that substrates such 
as 10 bind to the enzyme in a high energy 
conformation (Scheme 2) in which both 
phenol and proton source are in binding 
distance of the double bond. This insight 
led to a biomimetic synthesis of a-tocoph-
erol (1) using a large protecting group R 
and a dipeptide as steric constraints to gen-
erate a suitable conformation of the hydro-
quinone and providing a proton source,[11] 
see 11 (Scheme 3).
The general strategy to obtain a suitable 
precursor for cyclization to the chromanol 
system of vitamin E is outlined in Fig. 2. 
It was anticipated that cyclization would 
proceed with the chiral side chain leading 
directly to 1 as well as with the unsaturated 
side chain yielding a-tocotrienol (5) that 
could be enantioselectively hydrogenated 
to 1 using established methods.[11]
Accordingly, the synthesis of 1 started 
with the monoprotected hydroquionone 13 
which underwent a Mannich reaction with 
the proline derivative 14 (Scheme 4).[12] 
Subsequent esterification with campha-
noyl chloride and deprotection gave 15 
to which the protected aspartate 16 was 
added. The resulting phytyl phenol 17 was 
cyclized in the presence of pTsOH and 
furnished the protected chromanol dipep-
tide 18 in excellent yield. The benzylic 
amine of 18 was removed by hydrogena-
tion and the (2R,4’R,8’R)-tocopherylester 
19a obtained displaying 70% de (diastero-
meric excess). Systematic investigation 
of the cyclization reaction revealed that i) 
the de is independent of the camphanoyl 
unit (useful for de determination of the 
final product), ii) the de depends on the 
chirality of the dipeptide. For example if 
(S)-proline/(S)-aspartate were employed 
the (2S,4’R,8’R)-tocopheryl camphanate 
was obtained displaying 80% de. A similar 
reaction sequence was used to yield a-to-
cotrienyl acetatel (20, 65% de) which was 
subsequently hydrogenated to 19b in the 
presence of the catalyst 21.[11] 
The conversion of hydroquinone pre-
cursors such as 17 to chromanols gave sur-
prisingly high de values given the fact that 
the flexibly attached dipeptide is the only 
chirality inducing unit. To a certain extent 
this result validates the proposal that in the 
active site of tocopherol cyclase a high en-
ergy conformer of the phytylhydroquinone 
can cyclize even in the presence of weak 
acids. 
2.2 Organocatalytic Keysteps for 
the Synthesis of Chromanols
2.2.1 Organocatalysis Using Chiral 
 Dioxetans
The retrosynthetic plan of this ap-
proach to a-tocopherol (1) is depicted in 
Scheme 5. The sequence poses two prob-
lems: i) enantioselective epoxidation of a 
triply substituted double bond lacking ad-
jacent functionalization, see 22, and ii) re-
gioselective, ‘anti-Baldwin’ ring opening 
of the epoxide 23 to form the 6-membered 
chromane system 24 without racemization.
Regarding enantioselective epoxidation 
we considered the application of organo-
catalysts developed by Zhao and Shi.[13] 
This group has reported that fructose-de-
rived compounds such as 25 (+ H2O2) cata-
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Scheme2.Reactionmechanismoftocopherolcyclase.
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lyze the formation of chiral epoxides pro-
vided the olefin contains groups R3 and R4 
that are very different in size (Scheme 6).
In principle this is not the case for ole-
fin 22 as both groups adjacent to the dou-
ble are CH2. Nevertheless, we believed we 
could optimize the substrate through the 
substituents at the hydroquinone. Screen-
ing substrates with nine variations for R1/
R2 we found one outstanding result for 26 
which gave epoxide 27 in 81% yield and 
97% de (Scheme 7).
In order to accomplish the formation 
of the chromane system under inversion 
of configuration we first used conditions 
reported by Vilotijevic and Jamison[14] 
which favored pyran products in MeOH. 
However, a mono-protected epoxyphytyl 
hydroquinone gave exclusively the fu-
ran product following Baldwin’s rule.[15] 
A systematic investigation (21 experi-
ments) of the epoxide ring opening fi-
nally revealed that the epoxide 28 could 
be cyclized in acetonitrile/2M HCl-ether 
to the 3-hydroxy chromane 29 in 79% 
yield (Scheme 8). Removal of the hy-
droxyl group went smoothly through the 
corresponding tosylate, easily eliminated 
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Scheme4.Biomimeticsynthesisofa-tocopheryl-anda-tocotrinenyl
esters.
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Scheme5.Retrosynthesisinordertoobtainchiralchromanolsviaregioselectiveepoxidering
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Scheme9.Proline-catalyzeddomino-aldol-oxa-Michaelreactionof
phytal(31)andsalicylaldehyde32.
and directly hydrogenated to afford 30 
in almost quantitative yield and 93% de. 
Note that the small decrease of de from 
27 to 30 is due to the extent of carbenium 
ion formation during the conversion of 
28 to 29. Deprotection of 30 to 1 was ac-
complished by means of BF3.SMe2/AlCl3 
without epimerization at C(2).
2.2.2 Organocatalysis Using Proline 
Derivatives
In recent years organocatalysts derived 
from proline have been successfully ap-
plied for aldol and Mannich reactions.[16] 
We considered that a domino-aldol-oxa-
Michael reaction between phytal 31 and 
salicylaldehyde 32 catalyzed by 33 for 
example would either give aldehyde 34 or 
lactol 35 or a mixture of both (Scheme 9). 
From both intermediates one could envis-
age preparing a-tocopherol (1) by removal 
of the OH and CHO substituents at the het-
erocycle. Screening of ten different proline 
organocatalysts for the reaction between 
31 and 32 revealed that 36 (Scheme 10) 
was the best choice to obtain lactol 35 in 
60% yield and 97% de; the enantiomer of 
36 gave the diasteromeric lactol.[17]
The lactol 35 was oxidized to the ben-
zylic lactone 37 which was readily hydroge-
nated to afford the acid 38. Only two further 
steps, i.e. removal of one carbon and de-
methylation, are required to convert the key 
intermediate 38 into a-tocopherol (Scheme 
10). However conditions had to be carefully 
tuned to prevent racemization at C(2) due to 
thermal or acid-catalyzed ring opening/ring 
closure of the chromane system. Finally two 
procedures were found for the chain cleavage 
at C(2). Reduction of the acid 38 followed 
by oxidation gave the aldehyde 39 in 75% 
yield. Subsequent Rh-catalyzed decarbon-
ylation[18] furnished the tocopherol ether 30 
in 80% yield, 93% de. The same compound 
was obtained from 38 in 72% yield, 94% de 
using a Barton decarboxylation procedure.
[19]
 Ether cleavage was accomplished by 
treating 30 with BF3.Me2S/AlCl3; a-toco-
pherol (1) was obtained in 84% yield under 
retention of configuration at C(2). 
In summary, although the domino re-
action requires rather high concentrations 
(30ml%) of the proline derivative 36 the 
stereoselectivity and diastereoselectivity 
of this step are excellent providing one of 
the shortest procedures to obtain natural 
a-tocopherol (1). This strategy provides a 
general access to other members of the vi-
tamin E family and further to various natu-
ral products containing highly substituted, 
chiral chromanols[20] or xanthones.[21]
2.3 Coupling of Phenols with the 
Side Chain Containing the Re-
quired Three Chiral Centers
Several earlier syntheses of vitamin 
E compounds reported the preparation of 
the chiral chromanol using side chains 
that contain already all chiral centers.[6] 
Our unprecedented approach[22] employed 
the chiral key intermediate 40 which was 
planned to react under Mitsunobu condi-
tions with phenols 41 and 42 generating 
chiral phenolethers 43 and 44 that could 
be further elaborated for the preparation 
of 1 (Scheme 11). The a-hydroxyester 40 
was chosen because model reactions re-
vealed that replacement of the ester by CN, 
CH=CH2, CHO and propargyl substituents 
was unsatisfactory and gave <20% yield of 
phenol ethers.
Mitsunobu reaction of 40 with 41 or 42 
gave phenol ethers 43 and 44 with com-
plete inversion of configuration and 64% 
and 68% yield, respectively. As the thioke-
tal 45 derived from 44 did not cyclize in the 
presence of nBuLi[23] the corresponding 
bis-sulfone 46 was prepared[24] that gave 
the chromane 47 in 98% yield on treatment 
with NaOMe. Reductive removal of the di-
thiane tetroxide moiety was achieved with 
excess lithium naphthalenide yielding to-
copheryl methylether 30 in 86% yield and 
94% de (Scheme 12).
Alternatively 43 was reduced to alde-
hyde 48 and subsequent Wittig reaction, 
hydroboration and oxidation gave aldehyde 
49 that cyclized in the presence of TFA to 
furnish the chromene 50 in excellent yield 
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(Scheme 13). Hydrogenation of 50 fol-
lowed by deprotection gave a-tocopherol 
(1) displaying 94% de.
The key step of both pathways to a-to-
copherol (1) is a carefully controlled Mit-
sunobu reaction that generates the required 
phenolether with high de. Consecutive ring 
closure to the chromane/chromene was ac-
complished by two different procedures 
without epimerization. 
3. Conclusion
Using a phytylhydroquinone deriva-
tive that allows for diastereoselective acid-
driven double bond activation we developed 
an enzyme-like formation of the chroma-
nol unit of a-tocopherol. Subsequently we 
employed two organocatalytic reactions as 
key steps towards diastereoisomerically en-
riched 1, and further a Mitsunobu reaction 
was used coupling a suitable phenol with a 
chiral a-hydroxyester under complete inver-
sion of configuration. Except for the biomi-
metic cyclization all other approaches gave 
1 displaying de well above 90%.
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